Findings

What do systematic reviews say?

5 questions · 6 findings · 3 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2 · 33.3%GRADE not reported 0 · 0%Very low 2 · 33.3%Low 2 · 33.3%Moderate 0 · 0%High 0 · 0%

Peginterferon plus ribavirin vs non‐pegylated interferon plus ribavirin

Discontinuation of medication due to adverse events · people with chronic hepatitis C

Peginterferon plus ribavirin showed no clear difference in adverse events leading to treatment discontinuation compared with non‐pegylated interferon plus ribavirin (low certainty).

1 finding from 1 review

Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C 2014 · Cochrane Headline outcomes only
RR 0.86 [0.68, 1.09]
15 studies · 4571 participants
Low

Pegylated interferon + ribavirin (24 weeks) + initial telepravir (12 weeks) vs pegylated interferon (48 weeks) + initial telepravir (12 weeks) + initial low dose ribavirin (12 + 36 weeks)

Adverse events · patients on HD with HCV infection

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Standard interferon plus ribavirin vs standard interferon

Adverse events · patients on HD with HCV infection

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Pegylated interferon plus ribavirin vs pegylated interferon alone

Adverse events · patients on HD with HCV infection

Pegylated interferon plus ribavirin may leads to higher adverse events compared with pegylated interferon alone (low certainty).

1 finding from 1 review

Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes only
RR 1.1 [1.01, 1.19]
1 study · 377 participants
Low

Intervention vs no intervention or control intervention (control)

Serious adverse events (number) ‐ pegylated interferon‐alpha plus ribavirin versus pegylated interferon‐alpha · people with acute hepatitis C infection

It is very uncertain whether intervention changes serious adverse events (proportion) ‐ pegylated interferon‐alpha… compared with no intervention or control intervention (control) (very low certainty).

2 findings from 1 review

Pharmacological interventions for acute hepatitis C infection 2018 · Cochrane Headline outcomes only
OR 1.72 [0.7, 4.21]
2 studies · 237 participants
Very low
Pharmacological interventions for acute hepatitis C infection 2018 · Cochrane Headline outcomes only
Rate ratio 2.74 [1.4, 5.33]
2 studies · 237 participants
Very low